Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Eloxx Pharmaceuticals, Ltd.. (11/21/13). "Press Release: Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing". Herzliya.

Organisations Organisation Eloxx Pharmaceuticals Ltd.
  Organisation 2 Roche (Group)
Products Product ELX-02 (Eloxx Pharmaceuticals)
  Product 2 venture capital
Index term Index term Eloxx Pharmaceuticals–SEVERAL: investment, 201311 initial closing of 1st financing round with Roche + Pontifax
Person Person Noiman, Silvia (Eloxx Pharmaceuticals 201708 CEO)
     


Eloxx to focus on the discovery of small molecule therapeutics that selectively induces ribosomal read-through of premature termination codons for the treatment of nonsense genetic diseases


Eloxx Pharmaceuticals, Ltd. today announced the initial closing of its first round of financing with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Pontifax, an Israeli VC firm leading the financing.

Eloxx Pharmaceuticals is based on a technology developed by Prof. Timor Bassov from the Technion – Israel Institute of technology – enabling selective and safe ribosomal readthrough of premature termination codons for the treatment of nonsense genetic diseases.

“We are very excited by the prospect of delivering novel therapeutic small molecules to patients suffering from nonsense genetic diseases. Eloxx has in-licensed from the Technion – a library of compounds developed by Prof. Timor Bassov that have shown excellent safety and efficacy preclinical data demonstrating the ability of the compounds to overcome nonsense mutations for the treatment of several genetic diseases. We look forward to developing a pipeline of small-molecule therapeutics that target genetic mutations caused by non-sense mutations with high unmet medical needs .” says Shmuel Tuvia, Eloxx Pharmaceuticals, COO.


About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Ltd., based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.


Contact:

Silvia Noiman, PhD, MBA
Executive Chairman
E-mail: noimana@012.net.il
Phone: +972-544-256978

Shmuel Tuvia, Ph.D.
COO
E-mail: shmulik@eloxxpharma.com
Phone: +972-54-5689094

   
Record changed: 2017-08-09

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Eloxx Pharmaceuticals Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px




» top